Fresenius acquires mAbxience stake as Fresenius stock costs EUR 43.68
Published on 10/03/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius SE & Co. KGaA announced on October 1, 2026, that it had acquired the remaining 45% of mAbxience Holding S.L. for a total consideration of up to EUR 750 million, according to EQS News. The transaction was signed and completed on September 30, 2026, and required no regulatory approvals.
Weekend trading
At 12:31 p.m. CEST on October 3, 2026, the Fresenius share was at EUR 43.68 in weekend trading at Lang & Schwarz. That was EUR 0.01, or plus 0.02 percent, above the EUR 43.67 close at Lang & Schwarz on October 2, 2026. The bid was EUR 43.52 and the ask was EUR 43.84. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Fresenius stock.
Last Xetra trading day
The reference close for the weekend indication was EUR 43.67 at Lang & Schwarz on October 2, 2026. Xetra and the primary exchanges are closed during the weekend-trading period.
mAbxience acquisition
Fresenius said the acquisition gives it full ownership of the biosimilars platform within Fresenius Kabi’s Biopharma business. The consideration includes a contingent payment of EUR 50 million tied to site approvals. Fresenius said the purchase will be funded through available liquidity and operating cash flow, with no new financing required, according to the company announcement.
mAbxience generated more than EUR 320 million in revenue in 2025, according to the release. Its portfolio includes four products on the market and eight candidates in development. The company operates three drug-substance facilities in Spain and Latin America and employs more than 1,300 people.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
